Dr. Vladislav Deigin: Manus Was Founded In 1993 To Research And Develop Novel Biopharmaceutical Medications And Nutritional Supplements

Manus Pharmaceuticals

MANUS was founded in 1993 to research and develop novel biopharmaceutical medications and nutritional supplements.

Our experienced personal consulting in the area of R&D in peptide design and synthesis, structure-functional modification, cosmetic and dermatology active peptides.

OUR HISTORY

Company Mission

Help to improve the quality of life through the development and production of original peptide drugs, cosmetics, and nutraceuticals. Provision of scientific information, educational, and consulting services in peptide bioregulation.
Corporate overview

Manus Pharmaceuticals (Canada) Ltd. (Manus) is a privately owned Canadian company established in 1993, focused on the research and development of novel, peptide-based biopharmaceutical medications, and nutraceutical supplements to successfully manage various immune, hematopoietic, and neurological diseases.

We have been developing a portfolio of promising novel drugs and drug candidates using our proprietary internationally patented discovery platform for exploring synthetic peptides.

Our experienced personal consulting in the areas of R&D in peptide design and synthesis, structure-functional modification, and cosmetic and active dermatology peptides.

Manus has a solid intellectual property position, with more than 50 patents issued worldwide for the compounds and scientific platform. In addition, the company holds patents in the United States, Canada, Eurasian, and the European Union countries.

Tell us about yourself?

HISTORY Dr. Vladislav Deigin is the founder of Manus Pharmaceuticals (Canada)Ltd., Peptos Pharma ltd. (Russia), and Pharma Bio Ltd. (Russia).

Dr. Deigin is the driving force behind the scientific research in peptide-based preparations for the drug IP held by Manus. Dr. Deigin has over 45 years of experience in scientific research in bioorganic chemistry, experimental immunology, and neuropeptides.

Dr. Deigin was granted the Doctor of Sciences in Biology and Immunology in 2000 and received his Ph.D. in Bioorganic Chemistry and Biotechnology in the world renowned Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences.

He is Professor at Russian Academy of Sciences. Dr. V. Deigin is the author of over 150 scientific publications and over 70 different international patents for inventions in biotechnology, peptide chemistry, and HPLC.

Dr. Deigin was the Deputy Minister of the Public Health of the Russian Federation from 1990 to 1992 and a Member of the Innovation Committee of the Supreme Soviet of the Russian Federation (parliamentary adviser) from 1992 to 1993.

If you could go back in time a year or two, what piece of advice would you give yourself?

At this time be more marketing oriented. I used to be involved in peptide pharmaceuticals, now I want to implement our peptides into supplement market.

What problem does your business solve?

PHARMACEUTICAL AND NUTRACEUTICAL PRODUCT DEVELOPMEN

What is the inspiration behind your business?

Over 45 years in PHARMACEUTICAL AND NUTRACEUTICAL PRODUCT DEVELOPMEN my inspiration to help people live healthy.

What is your magic sauce?

All my product developed are original and were (and are) protected by the patents. My “magic sauce” is the the ambition to create a new “magic bulled” for life threatening illnesses.

What is the plan for the next 5 years? What do you want to achieve?

Start manufacture and market in Canada and the USA our first in class supplement STVOLOGEN: A NEW SUPPLEMENT FOR MAINTAINING HEALTH AND LONGEVITY BY STIMULATING THE BODY’S STEM CELLS.

What is the biggest challenge you’ve faced so far?

Financial shortage and problem to find adequate partners for creation serious business partnership.

How do people get involved/buy into your vision?

I want to find serious marketing partners with suffusion financial ability to manufacture and market our first supplement and other products at development stage.